Efficacy and Safety of Local Intracoronary Drug Delivery in Treatment of No-Reflow Phenomenon: A Pilot Study

Journal of Interventional Cardiology

Volumn 29, Issue 5, 2016, Pages 496-504

  Abu Arab, Tamer ^a   Rafik, Ramy ^a   El Etriby, Adel ^a  

^a Ain Shams University Hospital   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; EPINEPHRINE; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRIC ACID DERIVATIVE; VERAPAMIL; CARDIOVASCULAR AGENT;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; BALLOON; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GUIDING CATHETER; HEART ARRHYTHMIA; HEART DISEASE; HUMAN; HYPOTENSION; INTRACORONARY DRUG ADMINISTRATION; LENGTH OF STAY; LOADING DRUG DOSE; MALE; MICROCATHETER; NO REFLOW PHENOMENON; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PERFUSION BALLOON; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ADVERSE EFFECTS; AGED; CORONARY BLOOD VESSEL; DIAGNOSTIC IMAGING; DRUG EFFECTS; HEART MUSCLE REPERFUSION; INTRAARTERIAL DRUG ADMINISTRATION; MIDDLE AGED; NO-REFLOW PHENOMENON; PROCEDURES; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, BALLOON, CORONARY; CARDIOVASCULAR AGENTS; CORONARY ANGIOGRAPHY; CORONARY VESSELS; EPINEPHRINE; FEMALE; HUMANS; INJECTIONS, INTRA-ARTERIAL; MALE; MIDDLE AGED; MYOCARDIAL REPERFUSION; NO-REFLOW PHENOMENON; PILOT PROJECTS; TREATMENT OUTCOME; VERAPAMIL;

EID: 84989327812     PISSN: 08964327     EISSN: 15408183     Source Type: Journal    
DOI: 10.1111/joic.12318     Document Type: Article

References (25)

1. Ito H, Maruyama A, Iwakura K, et al. Clinical implications of the ‘no reflow’ phenomenon. A predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction. Circulation 1996; 93(2):223–228.
2. Resnic FS, Wainstein M, Lee MK, et al. No-reflow is an independent predictor of death and myocardial infarction after percutaneous coronary intervention. Am Heart J 2003; 145(1):42–46.
3. Piana RN, Paik GY, Moscucci M, et al. Incidence and treatment of ‘no-reflow’ after percutaneous coronary intervention. Circulation 1994; 89(6):2514–2518.
4. Niccoli G, Burzotta F, Galiuto L, et al. Myocardial no-reflow in humans. J Am Coll Cardiol 2009; 54(4):281–292.
5. Svilaas T, Vlaar PJ, van der Horst IC, et al. Thrombus aspiration during primary percutaneous coronary intervention. N Engl J Med 2008; 358(6):557–567.
6. Thiele H, Schindler K, Friedenberger J, et al. Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: The randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial. Circulation 2008; 118(1):49–57.
7. Lim SY, Bae EH, Jeong MH, et al. Effect of combined intracoronary adenosine and nicorandil on no-reflow phenomenon during percutaneous coronary intervention. Circ J 2004; 68(10):928–932.
8. Wilson RF, Laxson DD, Lesser JR, et al. Intense microvascular constriction after angioplasty of acute thrombotic coronary arterial lesions. Lancet 1989; 1(8642):807–811.
9. Chilian WM, Layne SM, Eastham CL, et al. Effects of epinephrine on coronary microvascular diameters. Circ Res 1987; 61(5 Pt 2):II47–II53.
10. Porto I, Ashar V, Mitchell AR. Pharmacological management of no reflow during percutaneous coronary intervention. Curr Vasc Pharmacol 2006; 4(2):95–100.
11. Choi JH, Chun KJ, Lee SH, et al. Usefulness of intracoronary epinephrine in severe hypotension during percutaneous coronary interventions. Korean Circ J 2013; 43(11):739–743.
12. Prasad A, Holmes DR. Percutaneous balloon angioplasty and general coronary intervention. In Mauro Moscucci MD, ed. Grossman & Bairn's Cardiac Catheterization, Angiography, and Intervention. Philadelphia: Lippincott Williams & Wilkins, 2014, p. 644.
13. Chesebro JH, Knatterud G, Roberts R, et al. Thrombolysis in myocardial infarction (TIMI) trial, phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 1987; 76(1):142–154.
14. Henriques JP, Zijlstra F, van ’t Hof AW, et al. Angiographic assessment of reperfusion in acute myocardial infarction by myocardial blush grade. Circulation 2003; 107(16):2115–2119.
15. Ramjane K, Han L, Jin C. The diagnosis and treatment of the no-reflow phenomenon in patients with myocardial infarction undergoing percutaneous coronary intervention. Exp Clin Cardiol 2008; 13(3):121–128.
16. Prati F, Capodanno D, Pawlowski T, et al. Local delivery versus intracoronary infusion of abciximab in patients with acute coronary syndromes. JACC Cardiovasc Interv 2010; 3(9):928–934.
17. Aksu T, Guler TE, Colak A, et al. Intracoronary epinephrine in the treatment of refractory no-reflow after primary percutaneous coronary intervention: A retrospective study. BMC Cardiovasc Disord 2015; 15(1):10.
18. Skelding KA, Goldstein JA, Mehta L, et al. Resolution of refractory no-reflow with intracoronary epinephrine. Catheter Cardiovasc Interv 2002; 57(3):305–919.
19. Maluenda G, Ben-Dor I, Delhaye C, et al. Clinical experience with a novel intracoronary perfusion catheter to treat no-reflow phenomenon in acute coronary syndromes. J Interv Cardiol 2010; 23(2):109–113.
20. Zhao YJ, Fu XH, Ma XX, et al. Intracoronary fixed dose of nitroprusside via thrombus aspiration catheter for the prevention of the no-reflow phenomenon following primary percutaneous coronary intervention in acute myocardial infarction. Exp Ther Med 2013; 6(2):479–484.
21. Ito H, Tomooka T, Sakai N, et al. Lack of myocardial perfusion immediately after successful thrombolysis. A predictor of poor recovery of left ventricular function in anterior myocardial infarction. Circulation 1992; 85(5):1699–1705.
22. Wu KC, Zerhouni EA, Judd RM, et al. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation 1998; 97(8):765–772.
23. Morishima I, Sone T, Okumura K, et al. Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction. J Am Coll Cardiol 2000; 36(4):1202–1209.
24. Poon K, Seth M, Dixon S, et al. The clinical implications and predictors of no reflow phenomenon in contemporary PCI: Insights from blue cross blue shield of Michigan cardiovascular collaborative Bmc2. J Am Coll Cardiol 2013; 61(10_S).
25. Li XD, Yang YJ, Hao YC, et al. Effect of pre-procedural statin therapy on myocardial no-reflow following percutaneous coronary intervention: A meta analysis. Chin Med J (Engl) 2013; 126(9):1755–1760.